NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: Results of the SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF)

被引:11
|
作者
McGrady, Michele [1 ]
Reid, Christopher M. [1 ]
Shiel, Louise [1 ]
Wolfe, Rory [2 ]
Boffa, Umberto [3 ]
Liew, Danny [4 ]
Campbell, Duncan J. [5 ]
Prior, David [5 ]
Stewart, Simon [6 ]
Krum, Henry [1 ]
机构
[1] Monash Univ, Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia
[2] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Univ Melbourne, Melbourne EpiCtr, Melbourne, Vic, Australia
[5] St Vincents Inst, Melbourne, Vic, Australia
[6] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
Asymptomatic left ventricular dysfunction; Heart failure; NT-proBNP; Risk factors; Epidemiology; SYSTOLIC DYSFUNCTION; GENERAL-POPULATION; DOPPLER-ECHOCARDIOGRAPHY; EMERGENCY DIAGNOSIS; EJECTION FRACTIONS; COST-EFFECTIVENESS; URBAN-POPULATION; ACUTE DYSPNEA; PREVALENCE; ELECTROCARDIOGRAM;
D O I
10.1016/j.ijcard.2013.08.089
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We assessed left ventricular dysfunction in a population at high risk for heart failure (HF), and explored associations between ventricular function, HF risk factors and NT-proB natriuretic peptide (NT-proBNP). Methods and results: 3550 subjects at high risk for incident HF (= 60 years plus = 1 HF risk factor), but without pre-existing HF or left ventricular dysfunction, were recruited. Anthropomorphic data, medical history and blood for NT-proBNP were collected. Participants at highest risk (n = 664) (NT-proBNP highest quintile; N30.0 pmol/L) and a sample (n = 51) from the lowest NT-proBNP quintile underwent echocardiography. Participants in the highest NT-proBNP quintile, compared to the lowest, were older (74 years vs. 67 years; p < 0.001) and more likely to have coronary artery disease, stroke or renal impairment. In the top NT-proBNP quintile (n = 664), left ventricular systolic impairment was observed in 6.6% (95% CI: 4 to 8%) of participants and was associated with male gender, coronary artery disease, hypertension and NT-proBNP. At least moderate diastolic dysfunction was observed in 24% (95% CI 20 to 27%) of participants and was associated with diabetes and NT-proBNP. In this high risk population, NT-proBNPwas associatedwith left ventricular systolic impairment (p < 0.001) and moderate to severe diastolic dysfunction (p < 0.001) after adjustment for age, gender, coronary artery disease, diabetes, hypertension and obesity. Conclusion: A high burden of ventricular dysfunctionwas observed in this high risk group. Combining NT-proBNP and HF risk factors may identify those with ventricular dysfunction. Thiswould allowresources to be focused on those at greatest risk of progression to overt HF. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 42 条
  • [21] Elevated B-type natriuretic peptide is associated with the presence of diastolic abnormalities in an asymptomatic, at-risk community population: The Screening TO Prevent Heart Failure (STOP HF) Study
    Conlon, C.
    O'Loughlin, C.
    Patle, A.
    Kinch, K.
    Whelan, A.
    Kelleher, C.
    Ledwidge, M.
    Mcdonald, K.
    EUROPEAN JOURNAL OF HEART FAILURE, 2007, 6 : 75 - 75
  • [22] Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction
    Ewald, B.
    Ewald, D.
    Thakkinstian, A.
    Attia, J.
    INTERNAL MEDICINE JOURNAL, 2008, 38 (02) : 101 - 113
  • [23] Benefits of Natriuretic Peptide Guided Heart Failure Therapy for Patients With Chronic Left Ventricular Systolic Dysfunction: Primary Results of the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study
    Januzzi, James
    Rehman, Shafiq U.
    Mohammed, Asim A.
    Bhardwaj, Anju
    Barajas, Linda
    Barajas, Justine
    Kim, Han-Na
    Baggish, Aaron L.
    Weiner, Rory B.
    Chen-Tournoux, Annabel A.
    Marshall, Jane E.
    Moore, Stephanie A.
    Carlson, William
    Lewis, Gregory D.
    Shin, Jordan
    Sullivan, Dorothy
    Parks, Kimberly
    Wang, Thomas
    Gregory, Shawn A.
    Uthamalingam, Shanmugam
    Semigran, Marc J.
    CIRCULATION, 2010, 122 (21) : 2221 - 2221
  • [24] "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis)
    Peters, Matthew N.
    Seliger, Stephen L.
    Christenson, Robert H.
    Hong-Zohlman, Susie N.
    Daniels, Lori B.
    Lima, Joao A. C.
    de Lemos, James A.
    Neeland, Ian J.
    deFilippi, Christopher R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (04):
  • [25] Natriuretic peptides and the Framingham Risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study
    Iacovoni, Attilio
    DeMaria, Renata
    Gavazzi, Antonello
    Grosu, Aurelia
    Fontana, Alessandra
    Guideri, Silvia
    Gori, Mauro
    Ferrari, Paola
    Filippi, Alessandro
    Rutili, Maria Rosaria
    Donzelli, Luigi
    Parolini, Marina
    Senni, Michele
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (05) : 5093 - 5095
  • [26] Comparison of Midregional pro-atrial natriuretic peptide and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death
    Moertl, Deddo
    Berger, Rudolf
    Struck, Joachim
    Gleiss, Alexandra
    Hammer, Alexandra
    Morgenthaler, Nils
    Bergmann, Andreas
    Huelsmann, Martin
    Pacher, Richard
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (15-16) : A33 - A34
  • [27] B-type natriuretic peptide (BNP) independently predicts left ventricular mass but is a suboptimal screening tool for systolic and diastolic dysfunction: The strong heart study
    Krauser, D
    Rodeheffer, RJ
    Burnett, JC
    Kizer, JR
    Best, LG
    Lee, ET
    Devereux, RB
    CIRCULATION, 2005, 112 (17) : U867 - U867
  • [28] Left Ventricular Ejection Fraction Assessment in Older Adults An Adjunct to Natriuretic Peptide Testing to Identify Risk of New-Onset Heart Failure and Cardiovascular Death?
    deFilippi, Christopher R.
    Christenson, Robert H.
    Kop, Willem J.
    Gottdiener, John S.
    Zhan, Min
    Seliger, Stephen L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (14) : 1497 - 1506
  • [30] Evaluation of N-terminal Pro-B-type natriuretic peptide (NT-proBNP) as a diagnostic test for ventricular dysfunction in patients with stable coronary heart disease and no history of heart failure.
    Corteville, D. C.
    Bibbins-Domingo, K.
    Ali, S.
    Wu, A.
    Schiller, N. B.
    Whooley, M. A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 : 54 - 54